0. DOCID:27008 SCORE: 0.00298578458015471
DOCNO: 11778749
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: surgery
QUALIFIER: methods
AUTHOR: V Nwakakwa V
AUTHOR: D Fleischer D
AFFILIATION: Division of Gastroenterology, Georgetown University Medical Center, Washington, DC 20007, USA.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Gastrointestinal endoscopy clinics of North America.
COUNTRY: United States
TITLE: Endoscopic mucosal resection of the esophagus: band ligation technique.
PUBDATE: 20010701
Endoscopic mucosal resection (EMR) is a minimally invasive endoscopic technique used in treating superficial cancers of premalignant lesions in the gastrointestinal tract. An attraction of this technique is that it can be curative with low morbidity, often providing the entire lesion for pathologic evaluation. The band ligation technique of EMR uses the existing technology of variceal band ligation to endoscopically place a band on flat mucosal lesions of the gastrointestinal tract to create a "pseudopolyp" before resection with an electrocautery snare. The band ligating technique and two variant band ligating devices are described.

1. DOCID:26039 SCORE: 0.00251496345421108
DOCNO: 11338019
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: genetics
AUTHOR: D S Schrump DS
AUTHOR: D M Nguyen DM
AFFILIATION: Thoracic Oncology Section, Surgery Branch, National Cancer Institute, National Institutes of Health, Building 10, Room 2B-07, 10 Center Drive, Bethesda, Maryland 20892-1502, USA. david_schrump@nih.gov
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: World journal of surgery.
COUNTRY: United States
TITLE: Targets for molecular intervention in multistep pulmonary carcinogenesis.
PUBDATE: 20010201
Lung cancers are a leading cause of mortality worldwide, and most of these neoplasms are directly attributable to tobacco abuse. Recent studies have begun to elucidate molecular mechanisms of multistep aero-digestive tract carcinogenesis, revealing novel targets for intervention in lung cancers and their precursor lesions. This review summarizes the molecular biology of lung cancers in relation to the prognosis and treatment of patients with these neoplasms.

2. DOCID:24716 SCORE: 0.00251377796329813
DOCNO: 11343961
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: secondary
QUALIFIER: secondary
QUALIFIER: pathology
AUTHOR: D Carroll D
AUTHOR: P B Rajesh PB
AFFILIATION: Department of Thoracic Surgery, Birmingham Heartlands Hospital, Bordesley Green East, B9 5SS, Birmingham, UK. danderosier@doctors.org.uk
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
COUNTRY: England
TITLE: Colonic metastases from primary squamous cell carcinoma of the lung.
PUBDATE: 20010501
Lung cancer is the most common malignancy in the UK. Metastasis to the colon is very rare and only infrequently symptomatic. Here we report a case of squamous cell carcinoma of the lung which presented with symptoms from a colonic metastasis.

3. DOCID:25410 SCORE: 0.00250815244015644
DOCNO: 10751464
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: radiography
QUALIFIER: methods
AUTHOR: K D Hopper KD
AUTHOR: K Singapuri K
AUTHOR: A Finkel A
AFFILIATION: Department of Radiology, Penn State University, Hershey, PA 17033, USA. khopper@psu.esu
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Radiology.
COUNTRY: UNITED STATES
TITLE: Body CT and oncologic imaging.
PUBDATE: 20000401
The most commonly used imaging modality in patients with cancer is computed tomography (CT). Whether to evaluate primary tumor or metastases to the neck, chest, abdomen, or pelvis, oncologic body CT has become invaluable to medical, gynecologic, and radiation oncologists. CT is the principal tool used to stage tumor, assess response, and guide radiation therapy. This review provides a discussion of how we optimize oncologic CT to best meet the needs of the patient with cancer.

4. DOCID:28930 SCORE: 0.00246438876268239
DOCNO: 15691805
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: genetics
AUTHOR: Somkiat Sunpaweravong S
AUTHOR: Patrapim Sunpaweravong P
AFFILIATION: Department of Surgery, Prince of Songkla University, Hat Yai, Songkla 90110, Thailand. susomkia@medicine.psu.ac.th
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Asian journal of surgery / Asian Surgical Association.
COUNTRY: China
TITLE: Recent developments in critical genes in the molecular biology of breast cancer.
PUBDATE: 20050101
The biology of breast cancer is complex, and the increasing knowledge of its molecular biology is having a great impact on the clinical management of this serious condition. This review looks at new findings on the role of various critical genes, including BRCA1, BRCA2, HER2 and p53, in the development of breast cancer and their clinical implications.

5. DOCID:30518 SCORE: 0.00240780100512058
DOCNO: 14763130
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: analogs & derivatives
QUALIFIER: therapeutic use
QUALIFIER: antagonists & inhibitors
QUALIFIER: therapeutic use
QUALIFIER: drug therapy
AUTHOR: John Lyons J
AUTHOR: Emel Bayar E
AUTHOR: Gil Fine G
AUTHOR: Michael McCullar M
AUTHOR: Randee Rolens R
AUTHOR: Joseph Rubinfeld J
AUTHOR: Craig Rosenfeld C
AFFILIATION: jlyons1@ireland.com
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Current opinion in investigational drugs (London, England : 2000)
COUNTRY: England
TITLE: Decitabine: development of a DNA methyltransferase inhibitor for hematological malignancies.
PUBDATE: 20031201
Decitabine (DAC) is a small molecule nucleotide analog that is incorporated into DNA and traps human DNA methyltransferases. Although initially developed as a cytotoxic agent, low-dose DAC is enjoying a revival as a specific inhibitor of hypermethylation in cancer. DAC has activity in several hematological diseases, especially myelodysplastic syndrome, chronic myelogenous leukemia and acute myeloid leukemia. Clinical and preclinical advances are presented in this review.

6. DOCID:30602 SCORE: 0.00240779942123737
DOCNO: 15649275
OWNER: NLM
STATUS: In-Data-Review
AUTHOR: Mary J Feeney MJ
AFFILIATION: Los Altos, California, USA.
PUBTYPE: Journal Article
JOURNALTITLE: Clinical and experimental pharmacology & physiology.
COUNTRY: Australia
TITLE: Fruits and the prevention of lifestyle-related diseases.
PUBDATE: 20041201
SUMMARY 1. Fruits contain a variety of compounds that may slow or prevent chronic diseases through a variety of possible mechanisms. Components in fruits thought to be associated with the reduction of these conditions include soluble and insoluble dietary fibre, anti-oxidant nutrients (vitamins C, E, selenium, beta-carotene) and phytonutrients (bioactive plant compounds that impart colour, flavour and other functional properties to foods). 2. The present paper briefly reviews selected studies on the role of some fruits in lifestyle conditions such as cardiovascular disease, some types of cancer and conditions that accompany ageing.

7. DOCID:31112 SCORE: 0.00223102570362584
DOCNO: 12420862
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: adverse effects
QUALIFIER: chemically induced
QUALIFIER: pathology
AUTHOR: H M Turk HM
AUTHOR: C Camci C
AUTHOR: S Buyukberber S
AUTHOR: B Tuncozgur B
AUTHOR: C Sivrikoz C
AUTHOR: L Elbeyli L
AUTHOR: I Sari I
AFFILIATION: Gaziantep University, Faculty of Medicine, Department of Medical Oncology, Turkey.
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: Journal of chemotherapy (Florence, Italy)
COUNTRY: Italy
TITLE: Superior vena cava syndrome caused by chemotherapy-induced fibrosis.
PUBDATE: 20020801
We report a case of a 51-year old man with small cell lung cancer who developed superior vena cava syndrome due to obstruction of the superior vena cava at the junction of the brachiocephalic vein by a fibrotic band, 2 months after completing six cycles of chemotherapy with cisplatin and etoposid. Superior vena cava syndrome caused by chemotherapy-induced pulmonary fibrosis should be kept in mind during follow-up.

8. DOCID:27051 SCORE: 0.00206423211073278
DOCNO: 10974622
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapy
QUALIFIER: metabolism
QUALIFIER: metabolism
AUTHOR: M J Piccart MJ
AUTHOR: A Di Leo A
AUTHOR: A Hamilton A
AFFILIATION: Institut Jules Bordet, Unite de Chimiotherapie, Rue Héger Bordet 1, B-1000, Brussels, Belgium. mpiccart@ulb.ac.be
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: European journal of cancer (Oxford, England : 1990)
COUNTRY: ENGLAND
TITLE: HER2. a 'predictive factor' ready to use in the daily management of breast cancer patients?
PUBDATE: 20000901
The past few years have witnessed an exponential increase in studies trying to identify molecular markers in patients with breast tumours that might predict for the success or failure of hormonal therapy or chemotherapy. HER2, a tyrosine kinase membrane receptor of the epidermal growth factor receptor family, has been the most widely studied marker in this respect. This paper attempts to critically review to what extent HER2 may improve 'treatment individualisation' for the breast cancer patient.

9. DOCID:26992 SCORE: 0.00205080738221085
DOCNO: 9651707
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Mass Screening
QUALIFIER: physiopathology
QUALIFIER: prevention & control
AUTHOR: J V McMurray JV
AUTHOR: T A McDonagh TA
AUTHOR: A P Davie AP
AUTHOR: J G Cleland JG
AUTHOR: C M Francis CM
AUTHOR: C Morrison C
AFFILIATION: MRC CRI in Heart Failure, University of Glasgow, U.K.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: European heart journal.
COUNTRY: ENGLAND
TITLE: Should we screen for asymptomatic left ventricular dysfunction to prevent heart failure?
PUBDATE: 19980601
A programme to detect and treat asymptomatic left ventricular dysfunction would seem to fulfil all five principles of screening. Indeed, such a programme would appear to be at least as firmly based as those already in existence for, for example, cervical and breast cancer. Further evaluation of the screening of high risk groups to detect asymptomatic left ventricular systolic dysfunction with the aim of giving treatment to prevent the development of heart failure is merited.

10. DOCID:27617 SCORE: 0.0020297655747705
DOCNO: 9691512
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: adverse effects
QUALIFIER: adverse effects
QUALIFIER: complications
QUALIFIER: drug therapy
AUTHOR: G Vanegas G
AUTHOR: C Ripamonti C
AUTHOR: A Sbanotto A
AUTHOR: F De Conno F
AFFILIATION: Pain Therapy and Palliative Care Division, National Cancer Institute, Milan, Italy.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Cancer nursing.
COUNTRY: UNITED STATES
TITLE: Side effects of morphine administration in cancer patients.
PUBDATE: 19980801
According to the World Health Organization (WHO) guidelines, oral morphine is the first choice drug for treating moderate to severe cancer-related pain. The fear of the side effects caused by this drug and the scarce information about prevention and management of these effects are the main reasons for the underuse of morphine. The aim of this paper is to provide a review of the literature on the side effects most frequently present both in the titration phase and during chronic administration of oral morphine and to describe the appropriate treatment.

11. DOCID:27811 SCORE: 0.0019906308035123
DOCNO: 10733867
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: metabolism
QUALIFIER: metabolism
QUALIFIER: pharmacology
QUALIFIER: analogs & derivatives
AUTHOR: H T Idriss HT
AFFILIATION: School of Biomedical Sciences, University of St. Andrews, North Haugh, Fife, KY16 9ST, Scotland. hi@st-and.ac.uk
PUBTYPE: Journal Article
JOURNALTITLE: Nitric oxide : biology and chemistry / official journal of the Nitric Oxide Society.
COUNTRY: UNITED STATES
TITLE: Do TNF-alpha-insensitive cancer cells escape alpha-tubulin nitrotyrosination?
PUBDATE: 20000201
TNF-alpha induces tumor-selective cytotoxicity in certain cancers, but many tumors are resistant to the effects of this inflammatory cytokine. This brief hypothesis outlines my views that nitric oxide-mediated alpha-tubulin posttranslational nitrotyrosination may be a major mechanism through which TNF-alpha exerts its cytotoxic effects on cancer cells. Additionally, I propose that tumor cells that are resistant to the effects of TNF-alpha may be so because of suppressed levels of "tubulin tyrosine ligase," which is responsible for the posttranslational tyrosination of alpha-tubulin.

12. DOCID:29731 SCORE: 0.00197867837568008
DOCNO: 14552834
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Repressor Proteins
QUALIFIER: physiology
QUALIFIER: physiology
QUALIFIER: genetics
QUALIFIER: physiology
QUALIFIER: physiology
AUTHOR: Frank M Raaphorst FM
AFFILIATION: Department of Pathology, VU Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands. fm.raaphorst@vumc.nl
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Trends in immunology.
COUNTRY: England
TITLE: Self-renewal of hematopoietic and leukemic stem cells: a central role for the Polycomb-group gene Bmi-1.
PUBDATE: 20031001
Self-renewal of hematopoietic stem cells is vital for the sustained daily production of blood cells. Two recent studies have shown that the Polycomb-group gene Bmi-1 is indispensable for regulation of self-renewal by normal and leukemic stem cells. This identifies Polycomb-group genes as potential targets for therapeutic intervention in leukemia, and possibly other forms of cancer.

13. DOCID:31874 SCORE: 0.00195023377499091
DOCNO: 15938138
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: chemistry
QUALIFIER: chemistry
QUALIFIER: chemistry
QUALIFIER: chemistry
QUALIFIER: chemistry
AUTHOR: Franco Ferrari F
AUTHOR: Franco Delle Monache F
AUTHOR: Alírica I Suárez AI
AUTHOR: Francisco Arvelo F
AUTHOR: Reinaldo S Compagnone RS
AFFILIATION: Istituto di Chimica del Riconoscimento Molecolare CNR, Università Cattolica del Sacro Cuore, Largo F. Vito 1, Rome, Italy.
PUBTYPE: Journal Article
JOURNALTITLE: Natural product research.
COUNTRY: England
TITLE: New cytotoxic isoflavone from the root bark of Brosimum utile.
PUBDATE: 20050601
A new isoflavone 5,7,4'-trihydroxy-3'-(3-hydroxy-3-methylbutyl)isoflavone (isowigtheone hydrate) (1), together with six known isoflavones 2-7 and (-)epicatechin, were isolated from the root barks of Brosimum utile. Their structures were established on the basis of spectroscopic evidence. The in vitro cytotoxic activity of the new compound 1 was evaluated against cell lines MCF7 (human breast carcinoma), PC3 (human prostate carcinoma), HT29 (human colon cancer) and human dermis fibroblasts.

14. DOCID:27791 SCORE: 0.00189337543237027
DOCNO: 11426654
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Immunotherapy, Adoptive
QUALIFIER: transplantation
QUALIFIER: therapy
AUTHOR: F O Nestle FO
AFFILIATION: Department of Dermatology, University of Zurich Medical School, Switzerland.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Oncogene.
COUNTRY: England
TITLE: Dendritic cell vaccination for cancer therapy.
PUBDATE: 20001201
A growing list of defined tumor-antigens opens the way to antigen specific immunotherapy of cancer. However current approaches are often limited in their potential to induce an effective anti-tumor response. Dendritic cells (DC) are natural adjuvants for the induction of antigen specific T cell response. They have been successfully used in clinical pilot trials to induce tumor specific immunity as well as clinical response in selected patients. Current research focuses on optimization of DC source, choice of antigen, antigen loading, mode of injection, as well as immuno-monitoring. Finally, a variety of immune escape mechanisms are operative at the tumor site and have to be overcome for successful vaccination.